Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

    ... Higher-risk myelodysplastic syndromes (MDS) frequently progress to secondary AML (sAML) within months even in the presence of continuous therapy ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias

    ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Let’s Go FISH-ing!

    ... diseases, particularly myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).  Targeted therapies are treatments ... are more frequently observed in 80% of patients with secondary MDS (MDS resulting from prior cancer treatment) vs. 40-60% of ...

    Article last updated 08/30/2018 - 1:28pm.

  4. Pediatric myelodysplastic syndromes: they do exist!

    ... malignancies in adults, myelodysplastic syndrome (MDS) is a heterogenous group of clonal disorders characterized by peripheral ... in ≥1 blood cell lineages. MDS frequently evolves to secondary acute myeloid leukemia with poor prognosis. Although uncommon among ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Only particular cytogenetic events are related to disease progression in sequential cytogenetic studies in myelodysplastic syndromes.

    ... in 76 patients with myelodysplastic syndromes (MDS) followed up to 82 months. Their karyotypes were followed routinely, ... transformation or reduced survival, since the majority of secondary cytogenetic changes in evolutive karyotypes of our patients were ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox

    ... regular transfusions of packed red blood cells leading to a secondary iron overload which might result in organ damage. Therefore, ... chelator which has been highly efficient in the treatment of secondary iron overload. Most frequent side effects of DFX are gastrointestinal ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Impact of the revised International Prognostic Scoring System cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndr

    ... in patients with myelodysplastic syndromes or secondary acute myeloid leukemia who were reported to the European Society for ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

    ... of patients with myelodysplastic syndromes (MDS) on a schedule of 15 mg/m(2) administered via intravenous (IV) infusion ... were > or = 18 years of age and had MDS ( de novo or secondary) of any French-American-British (FAB) subtype and an International ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine

    ... are standard therapy for myelodysplastic syndromes (MDS), and are often used to treat patients with acute myeloid leukemia (AML) ... or AML who were treated with decitabine after primary or secondary azacitidine failure at the University of Maryland Greenebaum Cancer ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... The myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal myeloid malignancies ... (AML). AML, which can occur de novo as well as secondary to MDS, is characterized by malignant clones of myeloid lineage in ...

    Research Article last updated 07/20/2018 - 5:15pm.